Condition

Cardiovascular Complication

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11
Recruiting7
Common interventions10
Lead sponsors shown11
Advertisement

Clinical trials

11 shown
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)NCT06785116 · 2025-03-02
RECRUITING
At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart FailureNCT06826534 · 2023-10-20
RECRUITING
Clinical Determinants and Adverse Reactions to Tropicamide/Phenylephrine in Hospitalized Patients.NCT07178600 · 2023-09-02
RECRUITING
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the CommunityNCT05349955 · 2022-11-21
RECRUITING
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer PatientsNCT04980716 · 2021-06-01
RECRUITING
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine CareNCT03882580 · 2019-03-01
RECRUITING
Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and MobilityNCT05407207 · 2018-06-01
RECRUITING
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)NCT06902857 · 2024-04-18
ACTIVE_NOT_RECRUITING
N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes MellitusNCT05745090 · 2022-11-10
ACTIVE_NOT_RECRUITING
An 18-year Follow-up Study on OSA in a Population-based CohortNCT05077748 · 2021-10-20
COMPLETED
Impact of Platinum-based Cancer Treatment on Endothelial FunctionNCT04681560 · 2018-01-18
COMPLETED

Trial status mix

RECRUITING7
ACTIVE_NOT_RECRUITING2
COMPLETED2

Phase mix

NA3
PHASE31
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.